Oxford BioMedica (OXB) has announced a collaboration and licence agreement with Bioverativ to develop gene therapy products for the treatment of haemophilia. Under the terms of the agreement OXB will receive a $5m upfront payment, plus milestone payments (potentially worth in excess of $100m) and royalties on net sales of any commercialised products. This agreement further validates the value partners see in OXB’s LentiVector expertise and manufacturing capabilities. OXB now has multipl
16 Feb 2018
Oxford BioMedica - LentiVector platform expanding into haemophilia
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Oxford BioMedica - LentiVector platform expanding into haemophilia
Oxford BioMedica plc (OXB:LON) | 201 7.7 1.9% | Mkt Cap: 201.3m
- Published:
16 Feb 2018 -
Author:
Dr Daniel Wilkinson -
Pages:
2
Oxford BioMedica (OXB) has announced a collaboration and licence agreement with Bioverativ to develop gene therapy products for the treatment of haemophilia. Under the terms of the agreement OXB will receive a $5m upfront payment, plus milestone payments (potentially worth in excess of $100m) and royalties on net sales of any commercialised products. This agreement further validates the value partners see in OXB’s LentiVector expertise and manufacturing capabilities. OXB now has multipl